Cessation of clopidogrel before major abdominal procedures

Area of Science:

• Cardiology
• Gastroenterology
• Surgical Oncology

Background:

• Clopidogrel bisulfate is an antiplatelet medication.
• Abdominal operations carry risks, including bleeding.
• The optimal timing for clopidogrel bisulfate cessation before surgery is debated.

Purpose of the Study:

• To investigate the impact of clopidogrel bisulfate cessation timing on outcomes after abdominal operations.
• To determine if stopping clopidogrel bisulfate within 7 days of surgery affects postoperative complications.

Main Methods:

• Retrospective review of 104 patients undergoing abdominal operations while on clopidogrel bisulfate.
• Patients were categorized into two groups based on the last clopidogrel bisulfate use: less than 7 days (Group A) or 7 days or more (Group B) before surgery.

Main Results:

• Patients stopping clopidogrel bisulfate within 7 days (Group A) had higher rates of postoperative bleeding requiring blood transfusion (30% vs 13%) and intensive care unit admission (37% vs 18%).
• Overall mortality was higher in Group A (12% vs 2%).
• No significant difference in bleeding-related reoperation or mortality was observed between groups. Elective surgery patients did not show significant differences in mortality or ICU admission based on cessation timing.

Conclusions:

• Clopidogrel bisulfate use within 7 days of abdominal surgery is associated with increased postoperative bleeding, primarily managed by transfusion.
• For elective abdominal operations, preoperative clopidogrel bisulfate cessation timing within 7 days did not significantly impact mortality or ICU admission.
• A 7-day interval for clopidogrel bisulfate cessation is recommended when indicated, as perioperative risk does not significantly vary within this timeframe.